Vaccination against dengue: Challenges and current developments

Annual Review of Medicine

Volumn 67, Issue , 2016, Pages 387-404

  Guy, Bruno ^a   Lang, Jean ^a   Saville, Melanie ^a   Jackson, Nicholas ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Clinical trials; Flavivirus; Human; Immunology; Safety; Vaccine

Indexed keywords

DENGUE VACCINE; LIVE VACCINE;

ARTICLE; DENGUE; DRUG EFFICACY; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INDUSTRIALIZATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VACCINATION; VACCINE PRODUCTION; CLINICAL TRIAL (TOPIC); DENGUE VIRUS; DRUG DEVELOPMENT; IMMUNOLOGY; TECHNOLOGY;

CLINICAL TRIALS AS TOPIC; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DRUG DISCOVERY; HUMANS; TECHNOLOGY TRANSFER; VACCINES, ATTENUATED;

EID: 84954549961     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-091014-090848     Document Type: Article

References (93)

1. Bhatt S, Gething PW, Brady OJ, et al. (2013). The global distribution and burden of dengue. Nature 496: 504-7
2. Malavige GN, Fernando S, Fernando DJ, Seneviratne SL. (2004). Dengue viral infections. Postgrad. Med. J. 80: 588-601
3. WHO (2009). Dengue Guidelines for Diagnosis, Treatment, Prevention and Control. Http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf
4. Vaughn DW, Green S, Kalayanarooj S, et al. (2000). Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181: 2-9
5. Martina BE, Koraka P, Osterhaus AD. (2009). Dengue virus pathogenesis: an integrated view. Clin.Microbiol. Rev. 22: 564-81
6. Guzman MG, Halstead SB, Artsob H, et al. (2010). Dengue: a continuing global threat. Nat. Rev.Microbiol. 12: S7-S16
7. Rothman AL. (2011). Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat. Rev. Immunol. 11: 532-43
8. Kyle JL, Beatty PR, Harris E. (2007). Dengue virus infects macrophages and dendritic cells in a mouse model of infection. J. Infect. Dis. 195: 1808-17
9. Cerny D, Haniffa M, Shin A, et al. (2014). Selective susceptibility of human skin antigen presenting cells to productive dengue virus infection. PLoS Pathog. 10: e1004548
10. Ho LJ, Wang JJ, Shaio MF, et al. (2001). Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J. Immunol. 166: 1499-506
11. Schmid MA, Harris E. (2014). Monocyte recruitment to the dermis and differentiation to dendritic cells increases the targets for dengue virus replication. PLoS Pathog. 10: e1004541
12. Lin YW, Wang KJ, Lei HY, et al. (2002). Virus replication and cytokine production in dengue virus-infected human B lymphocytes. J. Virol. 76: 12242-49
13. Wang JP, Liu P, Latz E, et al. (2006). Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. J. Immunol. 177: 7114-21
14. Palmer DR, Sun P, Celluzzi C, et al. (2005). Differential effects of dengue virus on infected and bystander dendritic cells. J. Virol. 79: 2432-39
15. Azeredo EL, De Oliveira-Pinto LM, Zagne SM, et al. (2006). NK cells, displaying early activation, cytotoxicity and adhesion molecules, are associated with mild dengue disease. Clin. Exp. Immunol. 143: 345-56
16. Hershkovitz O, Zilka A, Bar-Ilan A, et al. (2008). Dengue virus replicon expressing the nonstructural proteins suffices to enhance membrane expression of HLA class I and inhibit lysis by human NK cells. J. Virol. 82: 7666-76
17. Green AM, Beatty PR, Hadjilaou A, Harris E. (2014). Innate immunity to dengue virus infection and subversion of antiviral responses. J. Mol. Biol. 426: 1148-60
18. King CA, Anderson R, Marshall JS. (2002). Dengue virus selectively induces human mast cell chemokine production. J. Virol. 76: 8408-19
19. Vervaeke P, Vermeire K, Liekens S. (2015). Endothelial dysfunction in dengue virus pathology. Rev. Med. Virol. 25: 50-67
20. Medin CL, Fitzgerald KA, Rothman AL. (2005). Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion. J. Virol. 79: 11053-61
21. Souza DG, Fagundes CT, Sousa LP, et al. (2009). Essential role of platelet-Activating factor receptor in the pathogenesis of dengue virus infection. PNAS 106: 14138-43
22. Avirutnan P, Mehlhop E, Diamond MS. (2008). Complement and its role in protection and pathogenesis of flavivirus infections. Vaccine 26(Suppl. 8): 100-7
23. Shresta S. (2012). Role of complement in dengue virus infection: protection or pathogenesis? mBio 3: e00003-12
24. Warke RV, Martin KJ, Giaya K, et al. (2008). TRAIL is a novel antiviral protein against dengue virus. J. Virol. 82: 555-64
25. Mathew A, West K, Kalayanarooj S, et al. (2011). B-cell responses during primary and secondary dengue virus infections in humans. J. Infect. Dis. 204: 1514-22
26. Weiskopf D, Angelo MA, de Azeredo EL, et al. (2013). Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD+ T cells. PNAS 110: 2046-53
27. Zellweger RM, Eddy WE, Tang WW, et al. (2014). CD8+ T cells prevent antigen-induced antibodydependent enhancement of dengue disease in mice. J. Immunol. 193: 4117-24
28. Zellweger RM, Miller R, Eddy WE, et al. (2013). Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog. 9: e1003723
29. Laoprasopwattana K, Libraty D, Endy TP, et al. (2007). Antibody-dependent cellular cytotoxicitymediated by plasma obtained before secondary dengue virus infections: potential involvement in early control of viral replication. J. Infect. Dis. 195: 1108-16
30. Montoya M, Gresh L, Mercado JC, et al. (2013). Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl. Trop. Dis. 7: e2357
31. Olkowski S, Forshey BM, Morrison AC, et al. (2013). Reduced risk of disease during postsecondary dengue virus infections. J. Infect. Dis. 208: 1026-33
32. Endy TP, Anderson KB, Nisalak A, et al. (2011). Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. PLoS Negl. Trop. Dis. 5: e975
33. Anderson KB, Gibbons RV, Cummings DA, et al. (2009). A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J. Infect. Dis. 209: 360-68
34. Sabin AB. (1952). Research on dengue duringWorld War II. Am. J. Trop. Med. Hyg. 1: 30-50
35. Snow GE, Haaland B, Ooi EE, Gubler DJ. (2014). Research on Dengue DuringWorld War II revisited. Am. J. Trop. Med. Hyg. 91: 1203-17
36. Halstead SB, Mahalingam S, Marovich MA, et al. (2010). Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect. Dis. 10: 712-22
37. Fink J, Gu F, Ling L, et al. (2007). Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl. Trop. Dis. 1: e86
38. Long HT, Hibberd ML, Hien TT, et al. (2009). Patterns of gene transcript abundance in the blood of children with severe or uncomplicated dengue highlight differences in disease evolution and host response to dengue virus infection. J. Infect. Dis. 199: 537-46
39. Simmons CP, Popper S, Dolocek C, et al. (2007). Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J. Infect. Dis. 195: 1097-107
40. Coller BA, Barrett AD, Thomas SJ. (2011). The development of dengue vaccines. Introduction. Vaccine 29: 7219-20
41. Kanesa-Thasan N, Edelman R, Tacket CO, et al. (2003). Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am. J. Trop. Med. Hyg. 69(6 Suppl.): 17-23
42. Sabchareon A, Lang J, Chanthavanich P, et al. (2002). Safety and immunogenicity of tetravalent liveattenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am. J. Trop. Med. Hyg. 66: 264-72
43. Sanchez V, Gimenez S, Tomlinson B, et al. (2006). Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-Attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 24: 4914-26
44. Guy B, Barrere B, Malinowski C, et al. (2011). From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29: 7229-41
45. Durbin AP, Kirkpatrick BD, Pierce KK, et al. (2011). Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29: 7242-50
46. Kirkpatrick BD, Durbin AP, Pierce KK, et al. (2015). Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J. Infect. Dis. 212: 702-10
47. Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. (2011). Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 29: 7251-60
48. George SL, Wong MA, Dube TJ, et al. (2015). Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial. J. Infect. Dis. 212: 1032-41
49. Coller BA, Clements DE, Bett AJ, et al. (2011). The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 29: 7267-75
50. Schmitz J, Roehrig J, Barrett A, Hombach J. (2011). Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 29: 7276-84
51. Diaz C, Lin L, Martinez LJ, et al. (2014). Phase 1 study of different formulations of a tetravalent dengue purified inactivated vaccine (DPIV): safety and immunogenicity data in healthy adults from Puerto Rico through month 7. Am. J. Trop. Med. Hyg. 91: Abstr. LB-3137
52. Guy B, Guirakhoo F, Barban V, et al. (2010). Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28: 632-49
53. WHO Expert Committee on Biological Standardization. (2011). Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). WHO Tech. Rep. Ser. No. 979, Annex 2 (replacement of Annex 1 of WHO Tech. Rep. Ser. No. 932). Geneva: World Health Organ
54. Monath TP, Seligman SJ, Robertson JS, et al. (2015). Brighton Collab. Viral Vector Vaccines Safety Working Group (V3SWG). Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine 33(1): 62-72
55. Monath TP, Myers GA, Beck RA, et al. (2005). Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals 33: 131-44
56. Mantel N, Girerd Y, Geny C, et al. (2011). Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine 29: 6629-35
57. Dubayle J, Vialle S, Schneider D, et al. (2015). Site-specific characterization of envelope protein N-glycosylation on Sanofi Pasteur's tetravalent CYD dengue vaccine. Vaccine 33: 1360-68
58. Brandler S, Brown N, Ermak TH, et al. (2005). Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am. J. Trop. Med. Hyg. 72: 74-81
59. Deauvieau F, Sanchez V, Balas C, et al. (2007). Innate immune responses in human dendritic cells upon infection by chimeric yellow fever dengue vaccines serotype 1 to 4. Am. J. Trop. Med. Hyg. 76: 144-54
60. Balas C, Kennel A, Deauvieau F, et al. (2011). Different innate signatures induced in human monocytederived dendritic cells by wild-Type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains. J. Infect. Dis. 203: 103-8
61. Guirakhoo F, Pugachev K, Zhang Z, et al. (2004). Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78: 4761-75
62. Guy B, Barban V, Mantel M, et al. (2009). Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am. J. Trop. Med. Hyg. 80: 302-11
63. Barban V, Mantel N, Harenberg A, et al. (2014). Protective immunity induced against DENV-2 intravenous challenge in non-human primates immunized with CYD vaccine clinical lots. Am. J. Trop. Med. Hyg. 91: Abstr. LB-3233
64. Guy B, Boaz M, Byers A, et al. (2014). Assessment of the qualitative immune response induced by the CYD tetravalent vaccine in human volunteers. Am. J. Trop. Med. Hyg. 91: Abstr. 575
65. Ravel G, Guy B, Mantel N, et al. (2012). Sanofi Pasteur live attenuated, tetravalent dengue vaccine toxicity, biodistribution and shedding study in cynomolgus monkeys. Am. J. Trop. Med. Hyg. 87: Abstr. 630
66. Higgs S, Vanlandingham DL, Klingler KA, et al. (2006). Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am. J. Trop. Med. Hyg. 75: 986-93
67. Kazimírová M, Mantel N, Raynaud S, et al. (2012). Evaluation of chimeric yellow fever 17D/dengue viral replication in ticks. Vector Borne Zoonotic Dis. 12: 979-85
68. McGee CE, Tsetsarkin KA, Guy B, et al. (2011). Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virus. PLoS ONE 6(8): e23247
69. McGee CE, Lewis MG, Claire MS, et al. (2008). Recombinant chimeric virus with wild-Type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J. Infect. Dis. 197: 693-97
70. McGee CE, Tsetsarkin K, Vanlandingham DL, et al. (2008). Substitution of wild-Type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J. Infect. Dis. 197: 686-92
71. Lefeuvre A. (2005). Caractérisation des interactions entre les cellules hépatiques et les souches sauvage et vaccinale du virus de la fièvre jaune: application à l'étude de virus fièvre jaune chimériques utilisés pour le développement d'un vaccin contre la dengue. Diplôme de Doctorat, Univ. Claude Bernard Lyon 1, No. 129-2005
72. Guy B, Chanthavanich P, Gimenez S, et al. (2004). Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-Attenuated tetravalent dengue vaccine. Vaccine 22: 3563-74
73. Byers A, Broder R, Moser J, et al. (2014). Serotype-specific dengue neutralizing antibody responses in FcgR expressing CV1 cells. Abstr. 833. Am. J. Trop. Med. Hyg. 91: 228-303
74. Timiryasova TM, Bonaparte MI, Luo P, et al. (2013). Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am. J. Trop. Med. Hyg. 88: 962-70
75. Roehrig JT, Hombach J, Barrett AD. (2008). Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral. Immunol. 21: 123-32
76. Morrison D, Legg TJ, Billings CW, et al. (2010). A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J. Infect. Dis. 201: 370-77
77. Poo J, Galan F, Forrat R, et al. (2011). Live-Attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr. Infect. Dis. J. 30: e9-e17
78. Capeding RZ, Luna IA, Bomasang E, et al. (2011). Live-Attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 29: 3863-72
79. Lanata CF, Andrade T, Gil AI, et al. (2012). Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 30: 5935-41
80. Leo YS, Wilder-Smith A, Archuleta S, et al. (2012). Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: phase II randomized controlled trial in Singapore. Hum. Vaccin. Immunother. 8: 1259-71
81. Qiao M, Shaw D, Forrat R, et al. (2011). Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am. J. Trop.Med. Hyg. 85: 724-31
82. Guirakhoo F, Kitchener S, Morrison D, et al. (2006). Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin. 2: 60-67
83. Guy B, Nougarede N, Begue S, et al. (2008). Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26: 5712-21
84. Harenberg A, Begue S, Mamessier A, et al. (2013). Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum. Vaccin. Immunother. 9: 2317-25
85. Dayan G, Galán-Herrera GF, Forrat R, et al. (2014). Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico. Hum. Vaccin. Immunother. 10: 2853-63
86. Sabchareon A, Wallace D, Sirivichayakul C, et al. (2012). Protective efficacy of the recombinant, liveattenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380: 1559-67
87. Capeding MR, Tran NH, Hadinegoro SR, et al. (2014). Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384: 1358-65
88. Villar L, Dayan GH, Arredondo-Garciá JL, et al. (2015). Efficacy of a tetravalent dengue vaccine in children in Latin America. N. Engl. J. Med. 372: 113-23
89. Hadinegoro SRS, Arredondo-Garciá JL, Capeding MR, et al. (2015). Efficacy and long-Term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 373: 1195-206
90. Gamble J, Bethell D, Day NP, et al. (2000). Age-related changes inmicrovascular permeability: a significant factor in the susceptibility of children to shock? Clin. Sci. 98: 211-16
91. Hanna-Wakim R, Yasukawa LL, Sung P, et al. (2009). Age-related increase in the frequency of CD4+T cells that produce interferon-gamma in response to staphylococcal enterotoxin B during childhood. J. Infect. Dis. 200: 1921-27
92. Jackson N, Boaz M, Hu B, et al. (2014). Investigations of the observed efficacy of theCYDtetravalent dengue vaccine in the phase 2b trial in Ratchaburi, Thailand. Abstr. 576. Am. J. Trop. Med. Hyg. 91: 149-228
93. Thomas SJ. (2013). Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development. Hum. Vaccin. Immunother. 9: 1587-90